DYNAVAX TECHNOLOGIES CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2024-12-27: Form 8-K; Period of report 2024-12-26; Description 1.01 Entry into a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders; Details 1.01.
- 2024-11-12: Form 8-K; Period of report 2024-11-08; Description 8.01 Other Events; Details 8.01.
- 2024-11-07: Form 8-K; Period of report 2024-11-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2024-10-29: Form 8-K; Period of report 2024-10-28; Description 1.01 Entry into a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2024-12-27 | 8-K | 2024-12-26 | 1.01 Entry into a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders | 1.01 Entry into a Material Definitive Agreement. 3.03 On December 26, 2024, Dynavax Technologies Corporation (the “Company”) entered into Amendment No. 1 (the “Amendment”) to the Rights Agreement, dated as of October 28, 2024, by and between the Company and Computershare Trust Company, N.A., as rights agent (as amended, the “Rights Agreement”). | d924954d8k.htm |
| 2024-11-12 | 8-K | 2024-11-08 | 8.01 Other Events | 8.01 On November 8, 2024, Dynavax Technologies Corporation (“Dynavax”) entered into an accelerated share repurchase (“ASR”) transaction under an agreement (the “ASR Agreement”) with Goldman Sachs & Co. LLC (“GS&Co.”), to repurchase an aggregate of $100.0 million (the “Repurchase Price”) of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). | d899938d8k.htm |
| 2024-11-07 | 8-K | 2024-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2024, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the quarter ended September 30, 2024. | dvax-20241107.htm |
| 2024-10-29 | 8-K | 2024-10-28 | 1.01 Entry into a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 3.03 The information appearing above under Item 1.01 above is incorporated herein by reference. 5.03 In connection with the adoption of the Rights Agreement described in Item 1.01 above, the Board approved an Amended and Restated Certificate of Designation establishing the Preferred Shares and the rights, preferences and privileges thereof (the “Certificate of Designation”). 7.01 On October 29, 2024, the Company issued a press release announcing the adoption of the Rights Plan. | d895459d8k.htm |
| 2024-08-06 | 8-K | 2024-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2024, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the quarter ended June 30, 2024. | dvax-20240806.htm |
| 2024-08-02 | 8-K | 2024-08-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective August 1, 2024, the Board of Directors of Dynavax Technologies Corporation (the “Company”) re-appointed Kelly MacDonald to serve as the Company’s Chief Financial Officer (principal financial officer) upon her return from maternity leave. | dvax-20240801.htm |
| 2024-05-24 | 8-K | 2024-05-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 The 2024 Annual Meeting of Stockholders of Dynavax Technologies Corporation (the “Company”) was held on May 23, 2024 in a virtual meeting format, pursuant to notice duly given (the “Annual Meeting”). 5.07 Proxies for the Annual Meeting were solicited by the board of directors of the Company (the “Board”) pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition to the Board’s solicitations. | dvax-20240523.htm |
| 2024-05-08 | 8-K | 2024-05-08 | 2.02 Results of Operations and Financial Condition | 2.02 On May 8, 2024, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the first quarter ended March 31, 2024. | dvax-20240508.htm |
| 2024-04-01 | 8-K | 2024-03-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 29, 2024, Dynavax Technologies Corporation (the “Company”) appointed Ryan Spencer to serve in a temporary capacity as Interim Chief Financial Officer (principal financial officer) of the Company while Kelly MacDonald is on maternity leave, commencing April 1, 2024. | dvax-20240329.htm |
| 2024-03-12 | 8-K | 2024-03-07 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. 1.02 The information set forth in Item 1.01 with respect to the Termination Agreement is incorporated by reference into this Item 1.02. | dvax-20240307.htm |
| 2024-02-22 | 8-K | 2024-02-22 | 2.02 Results of Operations and Financial Condition | 2.02 On February 22, 2024, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023. | dvax-20240222.htm |
| 2024-01-08 | 8-K | 2024-01-08 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On January 8, 2024, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its preliminary unaudited fourth quarter and full year 2023 financial highlights. 7.01 The Company has posted a presentation (the “Presentation”) to its website at www.dynavax.com, in the “Events & Presentations” subsection of the “News & Events” tab. | dvax-20240108.htm |